A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index; 160 of the 216 sources its claims cite were checked for support.
Abstract
Arrhythmogenic cardiomyopathy (ACM) is a genetic myocardial disorder marked by progressive cardiomyocyte loss, fibro-fatty replacement, ventricular arrhythmias, and risk of sudden cardiac death. Traditionally considered a structural and electrical disease driven by desmosomal dysfunction, emerging evidence redefines ACM as an inflammatory cardiomyopathy in which immune activation plays a central role. This review integrates genetic, molecular, experimental, and clinical data to highlight inflammation as a unifying feature of ACM. Desmosomal gene variants impair cell adhesion and also activate cardiomyocyte-intrinsic inflammatory pathways, including nuclear factor of kappa B (NFκB) and glycogen synthase kinase 3β (GSK3β) signaling, promoting cytokine release, immune cell recruitment, and fibrotic remodeling. Preclinical studies suggest inflammation precedes structural changes, indicating it may be an initiating event rather than a secondary response. Clinical and pathological findings support this model, with inflammatory infiltrates, circulating cytokines, and autoantibodies observed across disease stages. These processes often present as episodic "hot phases" resembling myocarditis, thus complicating diagnosis. The inflammatory landscape involves both innate and adaptive immunity, along with stromal and neuronal remodeling, contributing to arrhythmogenesis through gap junction disruption, calcium-handling abnormalities, and fibrosis. Environmental factors such as exercise, stress, and metabolic disturbances further modulate inflammatory pathways and disease expression. Therapeutically, this evolving perspective supports immunomodulatory approaches, including inhibition of NFκB, GSK3β, and cytokine signaling. Early clinical data on immunosuppressive and cytokine-directed therapies are promising, especially during active inflammatory phases, while gene-based strategies specifically address the underlying genetic defects. In conclusion, ACM should be recognized as an inflammatory cardiomyopathy shaped by interactions between genetic susceptibility and immune dysregulation. Integrating genetic and immunologic profiling may improve diagnosis, risk stratification, and treatment, ultimately leading to refined personalized therapeutic strategies.
Overview
CoChat Summary
## TL;DR
This narrative review argues that arrhythmogenic cardiomyopathy (ACM) should be understood as an inflammatory cardiomyopathy, not only a desmosomal structural/electrical disorder. It synthesizes clinical, pathological, experimental, and early therapeutic evidence showing that inflammation can precede remodeling and may be a treatment target.
## Key findings
- Desmosomal gene variants account for more than 60% of patient cases, and inflammatory infiltrates are reported in 60–88% of ACM patients, especially those who died suddenly.
- The review states that myocardial inflammation often appears as a “hot phase,” with features that can mimic myocarditis, including chest pain, recurrent troponin peaks, and LGE-MRI abnormalities; DGV-positive patients with myocarditis-like phenotypes are at increased risk of major ventricular arrhythmias and heart failure.
- In preclinical models, inflammatory signaling is described as an early event: snRNA-seq and other multi-omic analyses showed cardiomyocyte-intrinsic NFκB activation, recruitment of CCR2+ macrophages, and inflammatory-fibrotic niche formation before extensive fibrosis.
- Therapeutic examples reported include SB216763 improving ventricular ectopy, function, fibrosis, inflammation, normalization of ID proteins, and survival in two murine ACM models, and Tideglusib being evaluated in a Phase 2 TaRGET clinical trial.
## Methods
- Narrative review of ACM literature integrating genetic, molecular, experimental, and clinical evidence.
- The authors report searching PubMed for original clinical and preclinical papers using the keywords “ACM”, “inflammation” and “immunity.”
- The review synthesizes findings from in vivo and in vitro models, human biopsies, snRNAseq, CITE-seq/CITseq, spatial transcriptomics, imaging, and interventional studies.
## Limitations
- The paper states that myocardial inflammation is not homogeneously detected in all preclinical models and patients with ACM.
- The authors note that several other molecular mechanisms contribute to ACM onset and progression, so inflammation is not the only pathway.
- The text says prospective trials are still needed to formally assess the safety and efficacy of immunosuppressive and molecularly targeted therapies; this is evident from the review nature of the paper and the reliance on preclinical/early clinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
106 Valid · 4 Not valid · 21 Not checked · 38 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“growing evidence implicates immune-mediated inflammatory mechanisms in disease onset and progression [11,12].”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation source
The Introduction (page not supplied) says that inflammatory cells and an innate immune response in cardiac myocytes could contribute to ACM onset and progression. The Discussion adds evidence that inflammatory signaling is involved in ACM pathogenesis, matching the claim’s cautious wording. (LLM, conf=0.93)
- Supportedcites [12] Chelko, 2024, NFκB Signaling Drives Myocardial Injury via CCR2+ Macrophages in a Preclinical Model of Arrhythmogenic Cardiomyopathy, J. Clin. Investig. source
The Introduction states that growing evidence implicates inflammation in ACM pathogenesis. The Discussion reports that blocking NFκB signaling in cardiac myocytes attenuated disease in an ACM mouse model, supporting the claim that immune-mediated mechanisms contribute to disease progression. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prior works have shown elevated levels of circulating [22] and myocardial inflammatory cytokines and chemokines from DGV-linked ACM subjects [11,23] that have been observed across disease phases and phenotypes”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Partly supportedcites [22] Asimaki, 2011, Altered Desmosomal Proteins in Granulomatous Myocarditis and Potential Pathogenic Links to Arrhythmogenic Right Ventricular Cardiomyopathy, Circ. Arrhythm. Electrophysiol. sourceExperimental — accuracy not yet measured
The Results section, “Myocardial expression of cytokines in ARVC” (page unavailable), reports increased myocardial IL-17 and TNFα signals in ARVC cases, including five with documented desmosomal gene mutations. It does not establish that these elevations occur across disease phases or phenotypes. The paper also reports elevated circulating inflammatory mediators, but the citing sentence assigns the circulating finding to a different citation [22]. (LLM, conf=0.86)
- Partly supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation sourceExperimental — accuracy not yet measured
The Results section on cytokine production reports elevated inflammatory cytokines and chemokines in hearts of Dsg2-mutant ACM mice; the patient-derived cells studied were cultured cardiomyocytes, not myocardial samples. The paper does not establish that myocardial elevations occur in ACM subjects across disease phases and phenotypes. The circulating-level claim is attached to a different citation. (LLM, conf=0.87)
- Partly supportedcites [23] Hawthorne, R.N., Blazeski, A., Lowenthal, J., Kannan, S., Teuben, R., Disilvestre, D., Morrissette-Mcalmon, J., Saffitz, J.E., Boheler, K.R., and James, C.A. (2021). Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. J. Clin. Med., 10. sourceExperimental — accuracy not yet measured
Results §3.4 reports elevated inflammatory cytokines and chemokines in DSG2-mutant patient-derived cardiomyocytes and notes a prior finding in Dsg2-mutant mouse myocardium. It does not establish elevated levels in myocardial samples from human subjects across disease phases and phenotypes. The circulating-level claim is attached to a different citation in the citing sentence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent works have demonstrated CCR2+ macrophages are early and persistent drivers of cardiac inflammation in ACM [12].”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 2. Race to Discovery: Myocardial Inflammation as a Key Pathological Phenotype in ACM
What the sources say
- Partly supportedcites [12] Chelko, 2024, NFκB Signaling Drives Myocardial Injury via CCR2+ Macrophages in a Preclinical Model of Arrhythmogenic Cardiomyopathy, J. Clin. Investig. sourceExperimental — accuracy not yet measured
The Results section reports increased CCR2+ macrophages at 4, 6, 10, and 16 weeks in Dsg2mut/mut mouse hearts, and identifies CCR2+ monocytes and macrophages as a primary source of inflammatory mediators. This supports an early, sustained inflammatory role in that preclinical model, but the paper does not establish that CCR2+ macrophages are early and persistent drivers across patients with ACM. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“environmental modifiers such as endurance exercise [24,25,26,27,28,29,30], psychological stress [31,32,33], diet [34,35], alcohol [36], and metabolic dysregulation [37,38,39] have been shown to influence disease penetrance and progression, in part, through modulation of inflammatory processes.”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [24] Sawant, 2016, Safety of American Heart Association-Recommended Minimum Exercise for Desmosomal Mutation Carriers, Heart Rhythm source
- Not checked — no full text of the sourcecites [25] Jacobsen, 2025, Endurance Exercise Promotes Episodes of Myocardial Injury in Individuals with a Pathogenic Desmoplakin (DSP) Variant, Heart Rhythm source
- Partly supportedcites [26] James, 2013, Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy-Associated Desmosomal Mutation Carriers, J. Am. Coll. Cardiol. sourceExperimental — accuracy not yet measured
The Discussion sections on clinical course and the relationship between exercise and ARVD/C report that endurance exercise is associated with greater disease penetrance and worse outcomes in desmosomal mutation carriers. The proposed inflammatory mechanism is less certain: the paper says exercise “may facilitate” myocyte uncoupling leading to inflammation, rather than showing that modulation of inflammation mediates those outcomes. This citation is attached to endurance exercise, not the other modifiers listed in the sentence. (LLM, conf=0.85)
- Partly supportedcites [27] Sawant, 2014, Exercise Has a Disproportionate Role in the Pathogenesis of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in Patients without Desmosomal Mutations, J. Am. Heart Assoc. sourceExperimental — accuracy not yet measured
The Discussion (Main Findings; Study Findings) reports that intense endurance exercise is associated with earlier presentation, worse structural disease, and a more aggressive arrhythmic course in gene-elusive ARVD/C. The citation is attached to endurance exercise, not the other listed modifiers. Our copy does not establish that exercise acts through modulation of inflammatory processes. (LLM, conf=0.85)
- Partly supportedcites [28] Bosman, 2022, Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy, Circ. Arrhythm. Electrophysiol. sourceExperimental — accuracy not yet measured
Our copy supports the exercise limb of the claim: the 'WHAT IS KNOWN?' box states that 'Exercise is shown to promote disease progression of arrhythmogenic right ventricular cardiomyopathy and increase risk of ventricular arrhythmias,' and the Results/Conclusions (Exercise Dose and Incidence of VA; Conclusions) report a dose-dependent rise in sustained VA with athlete status (HR 2.53-2.91). However, no passage in our copy addresses modulation of inflammatory processes (searched: inflammation/inflammatory cascade/fibrofatty/pathophysiology) — that mechanistic attribution is absent, and the paper's own data are confined to ARVC (right ventricular) rather than ACM broadly, with its Discussion noting it 'was not designed to assess whether the exercise necessary to accelerate structural progression is the same as for VA risk' (Study Limitations). (LLM, conf=0.78)
- Partly supportedcites [29] Chelko, 2021, Exercise Triggers CAPN1-Mediated AIF Truncation, Inducing Myocyte Cell Death in Arrhythmogenic Cardiomyopathy, Sci. Transl. Med. sourceExperimental — accuracy not yet measured
The Discussion states that exercise can increase the risk of ACM progression, and the Results report prominent myocardial inflammation and immune-cell infiltration in exercised ACM-model mice (page numbers unavailable). The paper does not establish that inflammation mediates exercise’s effect on progression or demonstrate an effect on disease penetrance. The other listed modifiers have separate citations and are not assessed here. (LLM, conf=0.84)
- Partly supportedcites [30] Cerrone, 2022, Role of Plakophilin-2 Expression on Exercise-Related Progression of Arrhythmogenic Right Ventricular Cardiomyopathy: A Translational Study, Eur. Heart J. sourceExperimental — accuracy not yet measured
Our copy squarely supports the exercise limb of the claim: the Translational perspective states that 'Exercise also accelerates disease progression in patients with arrhythmogenic right ventricular cardiomyopathy' and the Introduction notes that in ARVC 'exercise significantly increases the risk for developing the cardiomyopathy, for its progression to failure, and for the occurrence of arrhythmias and sudden death,' reinforced by the mouse and human-athlete data (Discussion; 'Cardiac remodelling in plakophilin-2-deficient human athletes...'). However, the mechanism the claim attributes — modulation of inflammatory processes — is absent: searched for inflammation/inflammatory cytokines/immune response and no passage invokes inflammation; the paper's proposed mechanism is reduced 'desmosomal reserve', increased apoptosis, impaired trophic remodelling and loss of muscle mass, plus an exercise-induced transcriptomic switch affecting intercalated-disc/mitochondrial metabolism. So only the penetrance/progression part of what is attributed to this source is supported. (LLM, conf=0.75)
- Partly supportedcites [31] Agrimi, J., Scalco, A., Agafonova, J., Williams, L., Pansari, N., Keceli, G., Jun, S., Wang, N., Mastorci, F., and Tichnell, C. (2020). Psychosocial Stress Hastens Disease Progression and Sudden Death in Mice with Arrhythmogenic Cardiomyopathy. J. Clin. Med., 9. sourceExperimental — accuracy not yet measured
The citation is attached to psychological stress, not to the separately cited modifiers. The Results report an association between perceived stress and ACM severity in patients, while the mouse findings support a role for psychosocial stress in disease progression. The Discussion mentions heightened sensitivity to pro-inflammatory disorders in stressed rodents, but does not establish that inflammation mediates ACM progression in this study. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [32] James, 2012, General and Disease-Specific Psychosocial Adjustment in Patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Implantable Cardioverter Defibrillators: A Large Cohort Study, Circ. Cardiovasc. Genet. source
- Could not verifycites [33] Singh, 2021, Anxiety and Depression in Inherited Channelopathy Patients with Implantable Cardioverter-Defibrillators, Heart Rhythm O2 sourceExperimental — accuracy not yet measured
The Discussion reports anxiety and depression in patients with inherited channelopathies and ICDs, but does not link psychological stress to ACM penetrance or progression. Searches for stress, inflammatory processes, and the other listed modifiers found no passage addressing the claimed mechanism. (LLM, conf=0.76)
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that inflammatory processes may represent more than just an epiphenomenon of immune cell-mediated cardiomyocyte injury.”
§ A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease > 1. Introduction
What the sources say
- Supportedcites [11] Chelko, 2019, Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy, Circulation source
The Discussion (page not provided) reports that ACM disease alleles activate an innate immune response in cardiac myocytes independently of inflammatory cells. It also suggests that signaling within those myocytes may drive key clinical features, supporting the claim that inflammation is more than a byproduct of immune cell-mediated injury. (LLM, conf=0.94)
- Supportedcites [23] Hawthorne, R.N., Blazeski, A., Lowenthal, J., Kannan, S., Teuben, R., Disilvestre, D., Morrissette-Mcalmon, J., Saffitz, J.E., Boheler, K.R., and James, C.A. (2021). Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. J. Clin. Med., 10. source
The Discussion reports an intrinsic inflammatory pathway in DSG2-mutant cardiomyocytes that is independent of immune-cell infiltration. It also suggests that this pathway may drive immune-cell recruitment, supporting the claim that inflammation may be more than a byproduct of immune-cell-mediated injury. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
69 more claims · 41 with their cited sources checked
Create a free account to see all 169 claims and to verify the 22 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 9
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Marcus, F. I., McKenna, W. J., Sherrill, D., Basso, C., Bauce, B., Bluemke, D. A., Calkins, H., Corrado, D., Cox, M. G. P. J., Daubert, J. P., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.840827 · Cited by 2,676
Right Ventricular Dysplasia: A Report of 24 Adult Cases
Marcus, F. I., Fontaine, G. H., Guiraudon, G., Frank, R., Laurenceau, J. L., Malergue, C., & Grosgogeat, Y. (1982) · Circulation · doi:10.1161/01.cir.65.2.384 · Cited by 1,603
Corrado, D., Basso, C., Pavei, A., Michieli, P., Schiavon, M., & Thiene, G. (2006) · JAMA · doi:10.1001/jama.296.13.1593 · Cited by 1,559 · cited 1×
“Arrhythmogenic cardiomyopathy (ACM) is a genetically and phenotypically heterogeneous myocardial disorder characterized by progressive cardiomyocyte loss, immune cell infiltration, and fibro-fatty replacement of the ventricular myocardium [1–5].”
Corrado, D., Basso, C., Thiene, G., McKenna, W. J., Davies, M. J., Fontaliran, F., Nava, A., Silvestri, F., Blomstrom-Lundqvist, C., Wlodarska, E. K., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00332-x · Cited by 978
Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905 · cited 1×
“TGF-β 1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
Arrhythmogenic Right Ventricular Cardiomyopathy: Dysplasia, Dystrophy, or Myocarditis?
Basso, C., Thiene, G., Corrado, D., Angelini, A., Nava, A., & Valente, M. (1996) · Circulation · doi:10.1161/01.cir.94.5.983 · Cited by 890
Towbin, J. A., McKenna, W. J., Abrams, D. J., Ackerman, M. J., Calkins, H., Darrieux, F. C. C., Daubert, J. P., de Chillou, C., DePasquale, E. C., Desai, M. Y., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.05.007 · Cited by 846
James, C. A., Bhonsale, A., Tichnell, C., Murray, B., Russell, S. D., Tandri, H., Tedford, R. J., Judge, D. P., & Calkins, H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.033 · Cited by 710
Garcia-Gras, E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27751 · Cited by 623
Giacomelli, E., Meraviglia, V., Campostrini, G., Cochrane, A., Cao, X., van Helden, R. W. J., Krotenberg Garcia, A., Mircea, M., Kostidis, S., Davis, R. P., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.05.004 · Cited by 622
Frustaci, A., Russo, M. A., & Chimenti, C. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp249 · Cited by 604
A New Diagnostic Test for Arrhythmogenic Right Ventricular Cardiomyopathy
Asimaki, A., Tandri, H., Huang, H., Halushka, M. K., Gautam, S., Basso, C., Thiene, G., Tsatsopoulou, A., Protonotarios, N., McKenna, W. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808138 · Cited by 456
Corrado, D., van Tintelen, P. J., McKenna, W. J., Hauer, R. N. W., Anastastakis, A., Asimaki, A., Basso, C., Bauce, B., Brunckhorst, C., Bucciarelli-Ducci, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz669 · Cited by 366
Chen, S. N., Gurha, P., Lombardi, R., Ruggiero, A., Willerson, J. T., & Marian, A. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302810 · Cited by 275 · cited 5×
“Recent evidence implicates fibro-adipogenic progenitors and epicardial-derived cells as primary sources, and they typically show an epicardial to endocardial migration [77,79,83,84].”
InfluentialAsimaki, A., Kapoor, S., Plovie, E., Karin Arndt, A., Adams, E., Liu, Z., James, C. A., Judge, D. P., Calkins, H., Churko, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008008 · Cited by 274 · cited 2×
“Dysregulation of GSK3 β , involved in the suppression of the Wnt/ β -catenin pathway, has also been implicated in ACM pathogenesis, particularly in the promotion of fibrosis and inflammation, and is effectively inhibited by SB216763 in preclinical ACM models [60,74,116,117].”
James, C. A., Jongbloed, J. D. H., Hershberger, R. E., Morales, A., Judge, D. P., Syrris, P., Pilichou, K., Domingo, A. M., Murray, B., Cadrin-Tourigny, J., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.120.003273 · Cited by 238
Li, J., Patel, V. V., Kostetskii, I., Xiong, Y., Chu, A. F., Jacobson, J. T., Yu, C., Morley, G. E., Molkentin, J. D., & Radice, G. L. (2005) · Circulation Research · doi:10.1161/01.res.0000181132.11393.18 · Cited by 223
Sawant, A. C., Bhonsale, A., te Riele, A. S. J. M., Tichnell, C., Murray, B., Russell, S. D., Tandri, H., Tedford, R. J., Judge, D. P., Calkins, H., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001471 · Cited by 221
Pilichou, K., Remme, C. A., Basso, C., Campian, M. E., Rizzo, S., Barnett, P., Scicluna, B. P., Bauce, B., van den Hoff, M. J. B., de Bakker, J. M. T., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090641 · Cited by 210
Plakophilin-2 Is Required for Transcription of Genes That Control Calcium Cycling and Cardiac Rhythm
Cerrone, M., Montnach, J., Lin, X., Zhao, Y.-T., Zhang, M., Agullo-Pascual, E., Leo-Macias, A., Alvarado, F. J., Dolgalev, I., Karathanos, T. V., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00127-0 · Cited by 210 · cited 2×
“The cardiomyocyte-specific, tamoxifen-inducible Pkp2 knock-out ( Pkp2 -cKO) mouse model was originally described by Cerrone M and colleagues [65], who demonstrated that loss of PKP2 exclusively in adult cardiomyocytes is sufficient to cause ACM of right ventricular predominance, transcriptional…”
In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy.
Valente, M., Calabrese, F., Thiene, G., Angelini, A., Basso, C., Nava, A. K., & Rossi, L. (1998) · Europe PMC (PubMed Central) · Cited by 210
Asimaki, A., Tandri, H., Duffy, E. R., Winterfield, J. R., Mackey-Bojack, S., Picken, M. M., Cooper, L. T., Wilber, D. J., Marcus, F. I., Basso, C., et al. (2011) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.111.964890 · Cited by 194
Gomes, J., Finlay, M., Ahmed, A. K., Ciaccio, E. J., Asimaki, A., Saffitz, J. E., Quarta, G., Nobles, M., Syrris, P., Chaubey, S., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr472 · Cited by 194
Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy
Chelko, S. P., Asimaki, A., Lowenthal, J., Bueno-Beti, C., Bedja, D., Scalco, A., Amat-Alarcon, N., Andersen, P., Judge, D. P., Tung, L., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040676 · Cited by 192 · cited 10×
“ACM is increasingly recognized as an inflammatory disease where cardiomyocytes harboring DGVs lead to NF κ B activation, propagating inflammatory cascades that lead to ACM disease onset and progression [11].”
InfluentialSelf-citationCentral role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy
Chelko, S. P., Asimaki, A., Andersen, P., Bedja, D., Amat-Alarcon, N., DeMazumder, D., Jasti, R., MacRae, C. A., Leber, R., Kleber, A. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85923 · Cited by 180
Self-citationLombardi, R., da Graca Cabreira-Hansen, M., Bell, A., Fromm, R. R., Willerson, J. T., & Marian, A. J. (2011) · Circulation Research · doi:10.1161/circresaha.111.255075 · Cited by 161
Chatterjee, D., Fatah, M., Akdis, D., Spears, D. A., Koopmann, T. T., Mittal, K., Rafiq, M. A., Cattanach, B. M., Zhao, Q., Healey, J. S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy567 · Cited by 161 · cited 1×
“In parallel, elevated sera levels of anti-heart (e.g., anti-α - and β -myosin-heavy chains), anti-intercalated disc, and anti-desmoglein-2 autoantibodies have been reported in ACM and are strongly correlated with gap junction dysfunction and ventricular arrhythmias (VAs) [46–49].”
‘Hot phase’ clinical presentation in arrhythmogenic cardiomyopathy
Bariani, R., Cipriani, A., Rizzo, S., Celeghin, R., Bueno Marinas, M., Giorgi, B., De Gaspari, M., Rigato, I., Leoni, L., Zorzi, A., et al. (2021) · EP Europace · doi:10.1093/europace/euaa343 · Cited by 154
Noorman, M., Hakim, S., Kessler, E., Groeneweg, J. A., Cox, M. G. P. J., Asimaki, A., van Rijen, H. V. M., van Stuijvenberg, L., Chkourko, H., van der Heyden, M. A. G., et al. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2012.11.018 · Cited by 154
Acute Myocarditis Associated With Desmosomal Gene Variants
Ammirati, E., Raimondi, F., Piriou, N., Sardo Infirri, L., Mohiddin, S. A., Mazzanti, A., Shenoy, C., Cavallari, U. A., Imazio, M., Aquaro, G. D., et al. (2022) · JACC: Heart Failure · doi:10.1016/j.jchf.2022.06.013 · Cited by 150
Self-citationGenetics of Myocarditis in Arrhythmogenic Right Ventricular Dysplasia
Lopez-Ayala, J. M., Pastor-Quirante, F., Gonzalez-Carrillo, J., Lopez-Cuenca, D., Sanchez-Munoz, J. J., Oliva-Sandoval, M. J., & Gimeno, J. R. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.01.001 · Cited by 140
Right Ventricular Cardiomyopathy: Is There Evidence of an Inflammatory Aetiology?
Thiene, G., Corrado, D., Nava, A., Rossi, L., Poletti, A., Boffa, G. M., Daliento, L., & Pennelli, N. (1991) · European Heart Journal · doi:10.1093/eurheartj/12.suppl_d.22 · Cited by 129
Sudden Cardiac Death in Young Athletes
Finocchiaro, G., Westaby, J., Sheppard, M. N., Papadakis, M., & Sharma, S. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.032 · Cited by 115 · cited 1×
“These pathological features create a vulnerable substrate for cardiac dysfunction, malignant ventricular arrhythmias, and sudden cardiac death, with a disproportionate burden in young individuals and athletes [6,7].”
Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers
Sawant, A. C., te Riele, A. S. J. M., Tichnell, C., Murray, B., Bhonsale, A., Tandri, H., Judge, D. P., Calkins, H., & James, C. A. (2016) · Heart Rhythm · doi:10.1016/j.hrthm.2015.08.035 · Cited by 106
Caforio, A. L. P., Re, F., Avella, A., Marcolongo, R., Baratta, P., Seguso, M., Gallo, N., Plebani, M., Izquierdo-Bajo, A., Cheng, C.-Y., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043931 · Cited by 104
Song, J., Chen, L., Chen, X., Ren, J., Zhang, N., Tirasawasdichai, T., Hu, Z., Hua, W., Hu, Y., Tang, H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8329 · Cited by 103
Clinical characteristics and risk stratification of desmoplakin cardiomyopathy
Wang, W., Murray, B., Tichnell, C., Gilotra, N. A., Zimmerman, S. L., Gasperetti, A., Scheel, P., Tandri, H., Calkins, H., & James, C. A. (2022) · EP Europace · doi:10.1093/europace/euab183 · Cited by 103
Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy
Sommariva, E., Brambilla, S., Carbucicchio, C., Gambini, E., Meraviglia, V., Dello Russo, A., Farina, F. M., Casella, M., Catto, V., Pontone, G., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv579 · Cited by 101
Treating Life-Threatening Myocarditis by Blocking Interleukin-1*
Cavalli, G., Pappalardo, F., Mangieri, A., Dinarello, C. A., Dagna, L., & Tresoldi, M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001654 · Cited by 96
Ermakov, S., Gerstenfeld, E. P., Svetlichnaya, Y., & Scheinman, M. M. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2016.12.010 · Cited by 94
Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents
DeWitt, E. S., Chandler, S. F., Hylind, R. J., Beausejour Ladouceur, V., Blume, E. D., VanderPluym, C., Powell, A. J., Fynn-Thompson, F., Roberts, A. E., Sanders, S. P., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.022 · Cited by 94
Chelko, S. P., Keceli, G., Carpi, A., Doti, N., Agrimi, J., Asimaki, A., Beti, C. B., Miyamoto, M., Amat-Codina, N., Bedja, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf0891 · Cited by 92 · cited 4×
“This is potentiated by mitochondrial oxidative stress due to depleted thioredoxin-2 (TRX2) and TRX2 reductase (TXNRD2) stores, leading to impaired ROS buffering [29].”
InfluentialSelf-citationSwope, D., Cheng, L., Gao, E., Li, J., & Radice, G. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06188-11 · Cited by 91
Baritussio, A., Schiavo, A., Basso, C., Giordani, A. S., Cheng, C., Pontara, E., Cattini, M. G., Bison, E., Gallo, N., De Gaspari, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2496 · Cited by 90 · cited 1×
“Additionally, the presence of circulating autoantibodies represents a therapeutic target in ACM, and, as in myocarditis, anti-heart and anti-intercalated disc antibody positivity may help to predict the response to immunosuppressive therapy [109,110].”
Campuzano, O., Alcalde, M., Iglesias, A., Barahona-Dussault, C., Sarquella-Brugada, G., Benito, B., Arzamendi, D., Flores, J., Leung, T. K., Talajic, M., et al. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201022 · Cited by 90
Nikolaienko, R., Bovo, E., & Zima, A. V. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01775 · Cited by 89 · cited 2×
“Oxidative stress further promotes direct RyR2 modification via oxidation of cysteine residues [89], producing S-nitrosylation, S-glutathionylation, and intersubunit disulfide cross-linking, collectively increasing channel open probability and augmenting diastolic sarcoplasmic reticulum (SR) calcium…”
Protonotarios, A., Wicks, E., Ashworth, M., Stephenson, E., Guttmann, O., Savvatis, K., Sekhri, N., Mohiddin, S. A., Syrris, P., Menezes, L., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.083 · Cited by 85
Lin, Y.-N., Mesquita, T., Sanchez, L., Chen, Y.-H., Liu, W., Li, C., Rogers, R., Wang, Y., Li, X., Wu, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab419 · Cited by 83
Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79
Pérez-Hernández, M., van Opbergen, C. J. M., Bagwan, N., Vissing, C. R., Marrón-Liñares, G. M., Zhang, M., Torres Vega, E., Sorrentino, A., Drici, L., Sulek, K., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060454 · Cited by 72
James, C. A., Tichnell, C., Murray, B., Daly, A., Sears, S. F., & Calkins, H. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.960898 · Cited by 72 · cited 1×
“Right-dominant ACM: Patients with PKP2 variants classically present with right ventricular dominant disease and exhibit a unique vulnerability to environmental per-petrators [32].”
Hermida, A., Fressart, V., Hidden-Lucet, F., Donal, E., Probst, V., Deharo, J.-C., Chevalier, P., Klug, D., Mansencal, N., Delacretaz, E., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1423 · Cited by 71
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
Cavalli, G., Foppoli, M., Cabrini, L., Dinarello, C. A., Tresoldi, M., & Dagna, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00131 · Cited by 70 · cited 1×
“Anakinra has demonstrated improvements in symptoms and systolic function in myocarditis and inflammatory cardiomyopathy [113–115].”
Inflammation shapes pathogenesis of murine arrhythmogenic cardiomyopathy
Lubos, N., van der Gaag, S., Gerçek, M., Kant, S., Leube, R. E., & Krusche, C. A. (2020) · Basic Research in Cardiology · doi:10.1007/s00395-020-0803-5 · Cited by 65 · cited 1×
“NF κ B is activated downstream of desmosome disruption through increased mechanical stretch, endoplasmic reticulum (ER) stress, reactive oxygen species (ROS), and the autocrine production of cytokines [78].”
Wnt/β-catenin pathway in arrhythmogenic cardiomyopathy
Lorenzon, A., Calore, M., Poloni, G., De Windt, L. J., Braghetta, P., & Rampazzo, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17457 · Cited by 64
Arrhythmogenic Right Ventricular Cardiomyopathy Presenting as Clinical Myocarditis in Women
Scheel, P. J., Murray, B., Tichnell, C., James, C. A., Tandri, H., Calkins, H., Chelko, S. P., & Gilotra, N. A. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.090 · Cited by 62 · cited 3×
“Given that endomyocardial biopsies often reveal inflammatory infiltrates in patients with ACM, a differential diagnosis can be challenging between ACM and myocarditis [18,52].”
Self-citationApplications of Gene Therapy in Cardiomyopathies
Argiro, A., Bui, Q., Hong, K. N., Ammirati, E., Olivotto, I., & Adler, E. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.09.015 · Cited by 59
Desmoplakin Cardiomyopathy: Comprehensive Review of an Increasingly Recognized Entity
Brandão, M., Bariani, R., Rigato, I., & Bauce, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072660 · Cited by 59
Giuliodori, A., Beffagna, G., Marchetto, G., Fornetto, C., Vanzi, F., Toppo, S., Facchinello, N., Santimaria, M., Vettori, A., Rizzo, S., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy057 · Cited by 57
Wu, I., Zeng, A., Greer-Short, A., Aycinena, J. A., Tefera, A. E., Shenwai, R., Farshidfar, F., Van Pell, M., Xu, E., Reid, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00450-w · Cited by 57 · cited 3×
“In the study by Wu I and colleagues, restoration of PKP2 expression via AAV9-mediated gene therapy improved cardiac function and survival in Pkp2 -cKO mice [67].”
InfluentialPeretto, G., Sala, S., De Luca, G., Marcolongo, R., Campochiaro, C., Sartorelli, S., Tresoldi, M., Foppoli, L., Palmisano, A., Esposito, A., et al. (2020) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2020.05.013 · Cited by 56
Self-citationThe arrhythmogenic right ventricle. Dysplasia versus cardiomyopathy
Fontaine, G., Fontaliran, F., Rosas Andrade, F., Velasquez, E., Tonet, J., Jouven, X., Fujioka, Y., & Frank, R. (1995) · Heart and Vessels · doi:10.1007/bf01744901 · Cited by 55 · cited 1×
“…cell infiltration [8,9], considering inflammatory infiltrates are observed in 60–88% of patients with ACM and are especially common in patients who died suddenly [16,17], this disease is frequently misdiagnosed as myocarditis [18]. three specific keywords: “ACM”, “inflammation” and “immunity.””
Cerrone, M., Marrón-Liñares, G. M., van Opbergen, C. J. M., Costa, S., Bourfiss, M., Pérez-Hernández, M., Schlamp, F., Sanchis-Gomar, F., Malkani, K., Drenkova, K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab772 · Cited by 51 · cited 2×
“In Pkp2 -cKO mice, exercise enhanced cardiac dysfunction, but its effect was attenuated by exercise pre-training [30].”
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy
Bermúdez-Jiménez, F. J., Protonotarios, A., García-Hernández, S., Asensio, A. P., Rampazzo, A., Zorio, E., Brodehl, A., Arias, M. A., Ruiz, R. M., Fernández‐Armenta, J., et al. (2024) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2024.02.031 · Cited by 49
Zheng, G., Jiang, C., Li, Y., Yang, D., Ma, Y., Zhang, B., Li, X., Zhang, P., Hu, X., Zhao, X., et al. (2019) · Protein & Cell · doi:10.1007/s13238-018-0563-2 · Cited by 48
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition
De Luca, G., Campochiaro, C., Dinarello, C. A., Dagna, L., & Cavalli, G. (2018) · Annals of Internal Medicine · doi:10.7326/l18-0315 · Cited by 42
Hawthorne, R. N., Blazeski, A., Lowenthal, J., Kannan, S., Teuben, R., DiSilvestre, D., Morrissette-McAlmon, J., Saffitz, J. E., Boheler, K. R., James, C. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143061 · Cited by 41
Self-citationMcTiernan, C. F., Mathier, M. A., Zhu, X., Xiao, X., Klein, E., Swan, C. H., Mehdi, H., Gibson, G., Trichel, A. M., Glorioso, J. C., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303020 · Cited by 40
Peretto, G., De Luca, G., Villatore, A., Di Resta, C., Sala, S., Palmisano, A., Vignale, D., Campochiaro, C., Lazzeroni, D., De Gaspari, M., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.02.018 · Cited by 40
Self-citationGJA1-20k Rescues Cx43 Localization and Arrhythmias in Arrhythmogenic Cardiomyopathy
Palatinus, J. A., Valdez, S., Taylor, L., Whisenant, C., Selzman, C. H., Drakos, S. G., Ranjan, R., Hong, T., Saffitz, J. E., & Shaw, R. M. (2023) · Circulation Research · doi:10.1161/circresaha.122.322294 · Cited by 40 · cited 2×
“Experimental approaches to enhance gap junction integrity, such as delivery of the truncated Cx43 isoform, GJA1-20k, and other strategies, have improved electrical coupling and reduced arrhythmias in ACM models [96,121].”
Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Myocarditis
Tiron, C., Campuzano, Ó., Fernández-Falgueras, A., Alcalde, M., Loma-Osorio, P., Zamora, E., Caballero, A., Sarquella‐Brugada, G., César, S., Garcia-Cuenllas, L., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003408 · Cited by 38
Hall, C. L., Sutanto, H., Dalageorgou, C., McKenna, W. J., Syrris, P., & Futema, M. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0169-4 · Cited by 38 · cited 1×
“Desmosomal gene variants (DGVs) remain the most common genetic contributors, accounting for more than 60% of patient cases (Table 1) [10], and growing evidence implicates immune-mediated inflammatory mechanisms in disease onset and progression [11,12].”
Gasperetti, A., Muller, S. A., Peretto, G., Asatryan, B., Protonotarios, A., Laredo, M., Tarlet, P.-Y., Syrris, P., Carrick, R. T., Murray, B., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073919 · Cited by 36
Self-citationOxidized LDL‐dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy
Sommariva, E., Stadiotti, I., Casella, M., Catto, V., Dello Russo, A., Carbucicchio, C., Arnaboldi, L., De Metrio, S., Milano, G., Scopece, A., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114365 · Cited by 34
Bosman, L. P., Wang, W., Lie, Ø. H., van Lint, F. H. M., Rootwelt-Norberg, C., Murray, B., Tichnell, C., Cadrin-Tourigny, J., van Tintelen, J. P., Asselbergs, F. W., et al. (2022) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.121.010221 · Cited by 34
Chelko, S. P., Penna, V. R., Engel, M., Shiel, E. A., Centner, A. M., Farra, W., Cannon, E. N., Landim-Vieira, M., Schaible, N., Lavine, K., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci172014 · Cited by 32
Self-citationChungsomprasong, P., Hamilton, R., Luining, W., Fatah, M., Yoo, S.-J., & Grosse-Wortmann, L. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.11.020 · Cited by 31
Susceptibility to Innate Immune Activation in Genetically Mediated Myocarditis
Selgrade, D. F., Fullenkamp, D. E., Chychula, I. A., Li, B., Dellefave-Castillo, L., Dubash, A. D., Ohiri, J., Monroe, T. O., Blancard, M., Tomar, G., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180254 · Cited by 30
Agrimi, J., Scalco, A., Agafonova, J., Williams III, L., Pansari, N., Keceli, G., Jun, S., Wang, N., Mastorci, F., Tichnell, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123804 · Cited by 29 · cited 1×
“…the genetic origins of human ACM. b. Germline Dsg2 mut/mut Model The homozygous desmoglein-2 mutant ( Dsg2 mut/mut ) mouse model of ACM has been a critical preclinical model in the investigation of the inflammatory processes that contribute to disease pathogenesis in ACM [11,12,29,31,60–62].”
Self-citationGao, S., Puthenvedu, D., Lombardi, R., & Chen, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176320 · Cited by 28 · cited 1×
“Epicardial cells additionally contribute by transdifferentiating into fibro-adipogenic progenitors [104,105] via pathways described in Sections 4.2 and 4.4.”
InfluentialFu, M., Hua, X., Shu, S., Xu, X., Zhang, H., Peng, Z., Mo, H., Liu, Y., Chen, X., Yang, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-023-03232-8 · Cited by 27
Hippo Activation in Arrhythmogenic Cardiomyopathy
Hu, Y. W., & Pu, W. T. (2014) · Circulation Research · doi:10.1161/circresaha.113.303114 · Cited by 24
Apoptotic myocardial cell death in the setting of arrhytmogenic right ventricular cardiomyopathy
YAMAJI, K., FUJIMOTO, S., IKEDA, Y., MASUDA, K., NAKAMURA, S., SAITO, Y., & YUTANI, C. (2005) · Acta Cardiologica · doi:10.2143/ac.60.5.2004965 · Cited by 24
Roudijk, R. W., Verheul, L., Bosman, L. P., Bourfiss, M., Breur, J. M. P. J., Slieker, M. G., Blank, A. C., Dooijes, D., van der Heijden, J. F., van den Heuvel, F., et al. (2022) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2021.09.001 · Cited by 23 · cited 1×
“Arrhythmogenic cardiomyopathy (ACM) is a genetically and phenotypically heterogeneous myocardial disorder characterized by progressive cardiomyocyte loss, immune cell infiltration, and fibro-fatty replacement of the ventricular myocardium [1–5].”
Hordeaux, J., Ramezani, A., Tuske, S., Mehta, N., Song, C., Lynch, A., Lupino, K., Chichester, J. A., Buza, E. L., Dyer, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094279 · Cited by 23 · cited 1×
“Challenges remain, including vector specificity, immune responses to adeno-associated viruses, and rare reports of gene therapy-associated myocarditis [123,124].”
Ng, K. E., Delaney, P. J., Thenet, D., Murtough, S., Webb, C. M., Zaman, N., Tsisanova, E., Mastroianni, G., Walker, S. L. M., Westaby, J. D., et al. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03488-7 · Cited by 23 · cited 6×
“At this early timepoint, cardiomyocyte apoptosis was https://doi.org/10.3390/cells15100868 significantly increased and thus proposed as the trigger leading to inflammatory immune cell recruitment and subsequent cardiac remodeling [59].”
InfluentialCicenia, M., & Drago, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040098 · Cited by 21
Jacobsen, A. P., Chiampas, K., Muller, S. A., Gasperetti, A., Yanek, L. R., Carrick, R. T., Gordon, C., Tichnell, C., Murray, B., Calkins, H., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2024.12.035 · Cited by 20
Singh, S. M., Murray, B., Tichnell, C., McClellan, R., James, C. A., & Barth, A. S. (2021) · Heart Rhythm O2 · doi:10.1016/j.hroo.2021.06.001 · Cited by 18
Neves, R., Tseng, A. S., Garmany, R., Fink, A. L., McLeod, C. J., Cooper, L. T., Macintyre, C. J., Homb, A. C., Rosenbaum, A. N., Bois, J. P., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131173 · Cited by 18
Lu, W., Li, Y., Dai, Y., & Chen, K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.900810 · Cited by 18
Vanaja, I. P., Scalco, A., Ronfini, M., Bona, A. D., Olianti, C., Rizzo, S., Chelko, S. P., Corrado, D., Sacconi, L., Basso, C., et al. (2025) · The Journal of Physiology · doi:10.1113/jp286845 · Cited by 17
Self-citationScalco, A., Liboni, C., Angioni, R., Di Bona, A., Albiero, M., Bertoldi, N., Fadini, G. P., Thiene, G., Chelko, S. P., Basso, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091871 · Cited by 15 · cited 1×
“Bone marrow-derived mesenchymal stromal cells (BM-MSCs) exhibited enhanced migration to the hearts of Dsg2 mut/mut mice, where they heavily promoted alterations in cytoskeletal organization [61].”
Self-citationGaine, S., Rolland, T., Asatryan, B., Laredo, M., Sampognaro, J., Carrick, R. T., Peretto, G., Muller, S., Villatore, A., Murray, B., et al. (2025) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.02.023 · Cited by 14 · cited 2×
“…controlling inflammation may represent an adjunctive strategy in ACM-related arrhythmia management, enhancing responsiveness to pharmacological therapy and improving outcomes following catheter ablation but not currently replacing the need for an ICD in patients at high risk [57,91,107,108].”
Self-citationMetabolic Signature of Arrhythmogenic Cardiomyopathy
Volani, C., Rainer, J., Hernandes, V. V., Meraviglia, V., Pramstaller, P. P., Smarason, S., Pompilio, G., Casella, M., Sommariva, E., Paglia, G., et al. (2021) · Metabolites · doi:10.3390/metabo11040195 · Cited by 13
Histopathological Features and Protein Markers of Arrhythmogenic Cardiomyopathy
Bueno-Beti, C., & Asimaki, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.746321 · Cited by 12 · cited 1×
“Endomyocardial biopsies, post-mortem reports, and/or explanted hearts from patients with ACM have revealed that pro-inflammatory infiltrates invariably accompany myocyte depletion and fibro-fatty remodeling of the myocardium, specifically in areas of active cardiac injury [72].”
Celeghin, R., Risato, G., Beffagna, G., Cason, M., Marinas, M. B., Barbera, M. D., Facchinello, N., Giuliodori, A., Casas, R. B., Caichiolo, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01741-2 · Cited by 11
Peretto, G., Villatore, A., & Cooper, L. T. (2026) · Immunological Reviews · doi:10.1111/imr.70105 · Cited by 10 · cited 3×
“Histological findings are reminiscent of acute myocarditis and are often reflective of an active “hot phase” of ACM that is associated with accelerated disease progression [40,41].”
Self-citationRBM20 Truncating Variants and Human Cardiomyopathy
Floyd, B. J., Njoroge, J. N., Krysov, V. A., Gomes, B., Murtha, R., Aribeana, C. N., Cannie, D. E., Smith, E. D., Paldino, A., Brown, E. E., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0401 · Cited by 9
Centner, A. M., Shiel, E. A., Farra, W., Cannon, E. N., Landim-Vieira, M., Salazar, G., & Chelko, S. P. (2024) · Nutrients · doi:10.3390/nu16132087 · Cited by 8 · cited 1×
“Furthermore, environmental modifiers can amplify cytokine and fibrokine burden, such as the recent work by Centner A et al. that demonstrated high-fat diet (HFD) exposure in Dsg2 mut/mut mice dramatically elevates myocardial levels of adiponectin (AdipoQ) and fibroblast growth factor 1 (FGF1) [35].”
Self-citationTargeting arrhythmogenic macrophages: lessons learned from arrhythmogenic cardiomyopathy
Mesquita, T., & Cingolani, E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180482 · Cited by 8
Giordani, A. S., Pontara, E., Vicenzetto, C., Baritussio, A., Peloso Cattini, M. G., Bison, E., Re, F., Marcolongo, R., Joseph, S., Chatterjee, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226736 · Cited by 8
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy
Peretto, G., Rizzo, S., Menegon, A., Villatore, A., Veeraraghavan, R., Vignale, D., Castoldi, V., Perani, L., Canu, T., Panzeri, M. C., et al. (2025) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.02.025 · Cited by 8
Self-citationLandim-Vieira, M., Kahmini, A. R., Engel, M., Cannon, E. N., Amat-Alarcon, N., Judge, D. P., Pinto, J. R., & Chelko, S. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213909 · Cited by 7
Self-citationArrhythmogenic Cardiomyopathy or “Athlete’s Heart”?
Minopoli, T. C., Kanthagnani, K., Olivotto, I., Sharma, R., Papadakis, M., Sharma, S., & Finocchiaro, G. (2025) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.08.026 · Cited by 6
Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy
Zhang, J., Zanella, F., Ellis, M. W., Bradford, W. H., Gutierrez-Lara, E. J., Wang, T.-M., Fujita, K., Duron, C., Karakikes, I., Lyon, R. C., et al. (2026) · Circulation: Heart Failure · doi:10.1161/circheartfailure.125.013801 · Cited by 5 · cited 1×
“Experimental approaches to enhance gap junction integrity, such as delivery of the truncated Cx43 isoform, GJA1-20k, and other strategies, have improved electrical coupling and reduced arrhythmias in ACM models [96,121].”
Malhotra, N., Cavus, O., Wallace, M. J., Bobik, J. T., You, K., Takenaka, S. S., Abdallah, D., Mohler, E. J., Antwi-Boasiako, S., Murphy, N. P., et al. (2025) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.013 · Cited by 5
Self-citationShiel, E. A., Farra, W., Medarev, S. L., Ariyaratne, G. H. D. N., Cannon, E. N., Steiner, J. L., & Chelko, S. P. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00416.2025 · Cited by 5
Self-citationDesmosomes in Cell Fate Determination: From Cardiogenesis to Cardiomyopathy
Moazzen, H., Bolaji, M. D., & Leube, R. E. (2023) · Cells · doi:10.3390/cells12172122 · Cited by 4
Maione, A. S., Iengo, L., Sala, L., Massaiu, I., Chiesa, M., Lippi, M., Ghilardi, S., Florindi, C., Lodola, F., Zaza, A., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02232-8 · Cited by 4 · cited 2×
“The DLK1-NOTCH pathway is critical for this differentiation, as DLK1 suppresses adipogenic differentiation in healthy cardiomyocytes, and ACM cardiomyocytes showed reduced DLK1 levels and thus promoted adipogenic differentiation [100].”
Maintenance of Energy Metabolism Is an Integral Part of Plakophilin-2 and Desmosome Functions
Aycinena, J. A., Tefera, A. E., Perea‐Gil, I., Holbrook‐Smith, D., Williams, K., Shenwai, R., Farshidfar, F., Ryback, B. M., Foppe, K. S., Wu, I., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101428 · Cited by 4
Peretto, G., Basso, C., Esposito, A., Dagna, L., & Della Bella, P. (2025) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.02.010 · Cited by 4
Self-citationTao, W., Gong, M., & Ke, Z. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70554 · Cited by 4 · cited 1×
“Single-cell RNA sequencing has identified the TGF-β ligand–receptor interaction as a common cascade across cardiac cell types [102].”
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis
Patrizia Caforio, A. L., Marinas, M. B., Giordani, A. S., Celeghin, R., Baritussio, A., Cason, M., Vicenzetto, C., Scognamiglio, F., De Gaspari, M., Pinci, S., et al. (2025) · JACC: Heart Failure · doi:10.1016/j.jchf.2025.102640 · Cited by 4
Sommariva, E., Lippi, M., Bruttini, F., Cannata, F., Baggiano, A., Schiavone, M., Salina, G., Sabatino, M., Vettor, G., Sicuso, R., et al. (2025) · PLOS One · doi:10.1371/journal.pone.0332876 · Cited by 3
Red Flags for Differentiating Desmosomal “Hot‐Phase” Cardiomyopathy From Acute Myocarditis
Peretto, G., Piriou, N., Gasperetti, A., Bauce, B., Villatore, A., Trezza, A. F., Melot, A., Palmisano, A., Bassetto, G., Martini, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044887 · Cited by 3 · cited 5×
“DSP -linked ACM is strongly associated with a myocardial fibro-inflammatory phenotype and a higher frequency of episodic “hot phases,” typically manifesting in the left ventricle and frequently observed via LGE-MRI [52,70].”
InfluentialSelf-citationGuazzo, A., Perumal Vanaja, I., Di Bona, A., Bariani, R., Disalvo, M. C., Albiero, M., Kuperwasser, N., David, P., Celeghin, R., Di Mauro, V., et al. (2026) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2025.10.031 · Cited by 3
Giordani, A. S., Baritussio, A., Vicenzetto, C., Brigiari, G., Pilichou, K., Gregori, D., De Gaspari, M., Rizzo, S., Basso, C., & Caforio, A. L. P. (2025) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2025.05.005 · Cited by 3 · cited 1×
“Additionally, the presence of circulating autoantibodies represents a therapeutic target in ACM, and, as in myocarditis, anti-heart and anti-intercalated disc antibody positivity may help to predict the response to immunosuppressive therapy [109,110].”
Yeh, Y.-H., Ko, Y.-S., Chan, Y.-H., Lai, Y.-J., Chang, G.-J., Chang, C.-J., & Hsu, L.-A. (2026) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.125.005434 · Cited by 3 · cited 1×
“PPAR γ and TGF β inhibitors have also shown promise in animal models of ACM, while direct PPAR γ agonism (via Rosiglitazone) has demonstrated increased mortality in Dsg2 -mutant mice [87,88].”
(2026) · doi:10.1161/jaha.125.047447 · Cited by 2
Topological control of spontaneous failure in active nematic solids
Chen, S., Ricci, M., Tabatabai, A. P., Sun, Z. G., Witthaus, S., Shankar, S. D., Nitzan, M., & Murrell, M. P. (2026) · Nature Materials · doi:10.1038/s41563-026-02493-x · Cited by 2
Bertoli, G., Phadke, K., Cospito, A., Rizk, J. A., Zhang, M., Miliotou, E., Cammer, M., Deng, Y., Mezzano, V., Alu, M., et al. (2025) · doi:10.1101/2025.10.22.682160 · Cited by 2
Lin, X., Davidsohn, N., Boyce, S., McIntyre, M., Zhang, M., Gencarelli, M., Ascheim, D. D., Delmar, M., & Cerrone, M. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.02.030 · Cited by 1 · cited 1×
“Delivery of fibroblast growth factor 21 (FGF21) mitigated the phenotype in PKP2 ACM models [122].”
Prijic, S., Cerovic, I., Vukomanovic, V., Popovic, S., Popovic, M., Ninic, S., Krasic, S., & Zdravkovic, M. (2025) · Circulation: Heart Failure · doi:10.1161/circheartfailure.124.012713 · Cited by 1
Cited by
Urbanowicz, T. K., & Filipiak, K. J. (2026) · Cells · doi:10.3390/cells15141308 · Cited by 1
Metadata
- Authors
- Ariyaratne, G. H. D. N., Villatore, A., Peretto, G., & Chelko, S. P.
- Affiliations
- Florida State University (US)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Chelko, Stephen P.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2026-05-09
- Volume
- 15
- Issue
- 10
- Pages
- 868
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC13204042
- OpenAlex
- W7162287531
- Cited by
- 2
- References
- 123
- Citations by year
- 2026: 2
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Florida Heart Research Foundation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Keywords
- arrhythmogenic cardiomyopathy, inflammatory cardiomyopathy, immune activation, NF-κB signaling, GSK3β signaling, cytokines, autoantibodies, myocarditis, fibrosis, gap junctions, calcium handling, sudden cardiac death, immunomodulatory therapy, genetic susceptibility
- MeSH terms
- Animals, Arrhythmias, Cardiac, Desmosomes, Humans, Inflammation, Cardiomyopathies, Signal Transduction, Arrhythmogenic Right Ventricular Dysplasia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.